• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

The REAL problem

Anonymous

Guest
The real problem with diabetes is that you have 2 teams. The PC team is the most experienced in most cases.... and the you have new Speciality reps making more money that the PC reps that have the relationships and are doing the job! All speciality reps do is DRIVE... PC reps SELL!!! The SP reps are making 7000 more in bonus a year.....what a joke. Senior leadership needs to combine the teams.
 




The real problem with diabetes is that you have 2 teams. The PC team is the most experienced in most cases.... and the you have new Speciality reps making more money that the PC reps that have the relationships and are doing the job! All speciality reps do is DRIVE... PC reps SELL!!! The SP reps are making 7000 more in bonus a year.....what a joke. Senior leadership needs to combine the teams.

specialty reps only making that money in theory anyway-there is the potential to make more-the real cash is being laid out on IBSTAR team apidra bonus and MTIN-specialty reps AND PC are getting screwed royally